The combination of the drugs encorafenib (Braftovi) and cetuximab (Erbitux) in the first-line treatment of metastatic colorectal cancer with the BRAF V600E mutation significantly improved the overall response rate (ORR).[1] The BEACON CRC trial, the first randomized phase 3 trial, demonstrated that this combination prolonged overall survival (OS) to a median of 9.3 months versus 5.9 months in the cetuximab and irinotecan control group (hazard ratio 0.61; 95% CI 0.48–0.77; p<0.0001), reducing the risk of death by 39%.[1] The objective response rate was 20% versus 2% in the control group (p<0.0001) as assessed by an independent central review.[1] The combination showed a well-tolerated safety profile with no unexpected toxicities.[1] Patients with BRAF V600E-mutant mCRC generally have a poor prognosis and previously there were no approved targeted therapies specific to this group in Europe.[1] The European Commission approved this combination based on the results of the BEACON CRC study.[1]